ArticleCommunications biology2026
Combined epigenomic landscapes of 5mC, 5hmC, and 6mA modifications in papillary thyroid carcinogenesis.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Papillary thyroid carcinoma (PTC), though genetically characterized, lacks comprehensive epigenomic profiling. Here we present the first combined analysis of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), and 6-methyladenine (6mA) in PTC pathogenesis. Using mDIP-seq on matched tumor and adjacent normal tissues from six treatment-naïve patients, we mapped genome-wide distributions of these modifications, revealing distinct spatial patterns and tumor-specific differentially methylated regions (DMRs) with modification-specific functional partitioning. Silhouette-guided feature selection refined 7,117 DMRs to a 187-locus diagnostic panel achieving robust tumor-normal discrimination, with chromosomes 16 and 19 as recurrent epigenetic hotspots (2.1-7.9-fold enrichment). Integration of TCGA data revealed mutation-dependent epigenetic-transcriptional associations: BRAF-mutant tumors showed selective upregulation of epigenetically dysregulated genes, whereas RAS-mutant tumors displayed distinct transcriptional patterns. Co-expression network analysis highlighted disrupted transcriptional coordination in tumors. This work establishes a multidimensional epigenetic framework for PTC with combinatorial diagnostic signatures and condition-specific associations between DNA modifications and driver mutations (BRAF vs. RAS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.